Synopsis
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cysteine
2. Cysteine Hydrochloride
3. Half Cystine
4. Half-cystine
5. L Cysteine
6. L-cysteine
7. Zinc Cysteinate
1. 52-89-1
2. L-cysteine.hcl
3. L-cysteine Hydrochloride Anhydrous
4. L-cysteine, Hydrochloride
5. L-cysteine Hcl Anhydrous
6. (r)-cysteine Hydrochloride
7. (r)-2-amino-3-mercaptopropanoic Acid Hydrochloride
8. L-cysteine Hcl
9. L-(+)-cysteine Hydrochloride
10. Cysteine Hydrochloride
11. Cysteine Monohydrochloride
12. L-cysteine, Hcl
13. L-cysteine Monohydrochloride
14. Cysteine Hcl
15. Cystein Chloride
16. Cysteine Hcl (anhydrous)
17. Cysteine Hydrochloride (anhydrous)
18. Cysteine, L-, Hydrochloride
19. Cysteine Hydrochloride Anhydrous
20. L-cysteine, Hydrochloride (1:1)
21. Cysteine Chlorhydrate
22. L-cysteine (hydrochloride)
23. H-cys-oh.hcl
24. Nsc 8746
25. A9u1687s1s
26. 3-mercaptoalanine Hydrochloride
27. Ek 2367
28. Cysteine (as Hydrochloride)
29. Ccris 3613
30. Cysteine, L-, Monohydrochloride
31. Nsc-755898
32. Einecs 200-157-7
33. Wr 348
34. Cysteine-hcl
35. Unii-a9u1687s1s
36. Ai3-18781
37. L-cysteine Hydrochloride, Anhydrous
38. Mfcd00064553
39. Cysteine-hydrochloride
40. L-cysteinium Chloride
41. H-cys-oh?cl
42. L-cysteine Chlorhydrate
43. Dsstox_cid_367
44. L-cysteine Hydro-chloride
45. L-cysteine Hydrochloride;
46. Ec 200-157-7
47. Dsstox_rid_75543
48. Dsstox_gsid_20367
49. Schembl18161
50. L-cysteinemethyl Hydrochloride
51. L-2-amino-3-mercaptopropanoic Acid Monohydrochloride
52. Chembl1200630
53. Dtxsid0020367
54. Chebi:91247
55. Hy-y0337a
56. Tox21_200699
57. S4815
58. Akos015849225
59. Ccg-266272
60. Cs-w018517
61. Cysteine Hydrochloride [who-dd]
62. Cas-52-89-1
63. Cysteine Hydrochloride, Anhydrous
64. (r)-(+)-cysteine Hydrochloride Hydrate
65. Ncgc00258253-01
66. (2r)-2-amino-3-mercapto-propionic Acid
67. Ac-12796
68. As-11682
69. L-cysteine Hydrochloride [usp-rs]
70. L-cysteine Hydrochloride, 98.0-102.0%
71. Cysteine Hydrochloride Anhydrous [ii]
72. Cysteine Hydrochloride Anhydrous [mi]
73. (r)2-amino-3-thiopropanoic Acid Hydrochloride
74. E72644
75. (r)-2-amino-3-mercaptopropanoicacidhydrochloride
76. 064c553
77. A829298
78. (1r)-1-carboxy-2-sulfanylethan-1-aminium Chloride
79. (2r)-2-amino-3-sulfanylpropanoic Acid;hydrochloride
80. J-019666
81. L-cysteine Hydrochloride, Anhydrous, >=98% (tlc)
82. W-105789
83. L-cysteine Hydrochloride, Anhydrous, >=99.0% (rt)
84. Q27163158
85. L-cysteine Hydrochloride, Fg, Product Of Wacker Chemie Ag
86. L-cysteine Hydrochloride, Vetec(tm) Reagent Grade, >=98%
87. (2r)-2-amino-3-sulfanyl-propanoic Acid Hydrochloride;h-cys-oh.hcl
88. L-cysteine Hydrochloride, Anhydrous, From Non-animal Source, Bioreagent, Suitable For Cell Culture, >=98.0%
| Molecular Weight | 157.62 g/mol |
|---|---|
| Molecular Formula | C3H8ClNO2S |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 2 |
| Exact Mass | 156.9964274 g/mol |
| Monoisotopic Mass | 156.9964274 g/mol |
| Topological Polar Surface Area | 64.3 Ų |
| Heavy Atom Count | 8 |
| Formal Charge | 0 |
| Complexity | 75.3 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
Axplora- The partner of choice for complex APIs.
Certificate Number : R1-CEP 1997-014 - Rev 03
Issue Date : 2014-04-24
Type : Chemical
Substance Number : 895
Status : Valid
Date of Issue : 2022-06-24
Valid Till : 2025-07-02
Written Confirmation Number : WC-0102
Address of the Firm :
| Available Reg Filing : EU |
GDUFA
DMF Review : Reviewed
Rev. Date : 2017-10-27
Pay. Date : 2017-03-14
DMF Number : 8866
Submission : 1990-11-30
Status : Active
Type : II
Registration Number : 220MF10229
Registrant's Address : 452 Oshiba, Mobara City, Chiba Prefecture
Initial Date of Registration : 2008-11-17
Latest Date of Registration : --
NDC Package Code : 53884-1013
Start Marketing Date : 2023-01-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-08-14
Pay. Date : 2018-07-02
DMF Number : 21364
Submission : 2008-02-26
Status : Active
Type : II
Registration Number : 220MF10016
Registrant's Address : 575 Shimada-cho, Ashikaga City, Tochigi Prefecture
Initial Date of Registration : 2008-01-09
Latest Date of Registration : --
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2753
Submission : 1976-10-15
Status : Inactive
Type : II
NDC Package Code : 12497-1013
Start Marketing Date : 1978-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10741
Submission : 1994-02-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1930
Submission : 1972-05-09
Status : Inactive
Type : II
Registration Number : 217MF10553
Registrant's Address : 575 Shimada-cho, Ashikaga City, Tochigi Prefecture
Initial Date of Registration : 2005-09-09
Latest Date of Registration : --
NDC Package Code : 17333-909
Start Marketing Date : 2008-06-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2753
Submission : 1976-10-15
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 1930
Submission : 1972-05-09
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2018-08-14
Pay. Date : 2018-07-02
DMF Number : 21364
Submission : 2008-02-26
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10741
Submission : 1994-02-28
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2017-10-27
Pay. Date : 2017-03-14
DMF Number : 8866
Submission : 1990-11-30
Status : Active
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
Axplora- The partner of choice for complex APIs.
Axplora- The partner of choice for complex APIs.
Cysteine Hydrochloride Monohydrate
Certificate Number : R1-CEP 1997-014 - Rev 03
Status : Valid
Issue Date : 2014-04-24
Type : Chemical
Substance Number : 895
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] JDMF
Japanese Pharmacopoeia L-Ethylcysteine Hydrochloride
Registration Number : 219MF10005
Registrant's Address : 4-2-2 Nihonbashi Honcho, Chuo Ward, Tokyo
Initial Date of Registration : 2007-01-18
Latest Date of Registration : 2007-01-18
L-Cysteine hydrochloride (monohydrate) (Nippon Pro)
Registration Number : 217MF10553
Registrant's Address : 575 Shimada-cho, Ashikaga City, Tochigi Prefecture
Initial Date of Registration : 2005-09-09
Latest Date of Registration : 2007-08-07
Japanese Pharmacopoeia L-Cysteine Hydrochloride Hydrate "For manufacturing only"
Registration Number : 220MF10016
Registrant's Address : 575 Shimada-cho, Ashikaga City, Tochigi Prefecture
Initial Date of Registration : 2008-01-09
Latest Date of Registration : 2008-01-09
Japanese Pharmacopoeia L-Cysteine Hydrochloride Hydrate (for manufacturing only)
Registration Number : 220MF10229
Registrant's Address : 452 Oshiba, Mobara City, Chiba Prefecture
Initial Date of Registration : 2008-11-17
Latest Date of Registration : 2008-11-17
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
Axplora- The partner of choice for complex APIs.
L-Cysteine HCl Monohydrate Ph. Eur
Date of Issue : 2022-06-24
Valid Till : 2025-07-02
Written Confirmation Number : WC-0102
Address of the Firm : Plot No.B5 & B6, A1&A2, MEPZ- Tambaram, Chennai-600045
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
NDC Package Code : 17333-909
Start Marketing Date : 2008-06-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 12497-1013
Start Marketing Date : 1978-03-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 53884-1013
Start Marketing Date : 2023-01-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 10695-128
Start Marketing Date : 2024-06-03
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
Axplora- The partner of choice for complex APIs.
About the Company : Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-qual...
About the Company : The Ajinomoto Group Standards of Business Conduct (hereinafter the "Standards of Conduct") describe the conduct that every member of the Ajinomoto Group must understand and practic...
L-Cysteine Hydrochloride Monohydrate
About the Company : Apotex Pharmachem is a global fully integrated API R&D and manufacturing organization with its headquarters located in Brantford, Ontario, Canada and is a member of the Apotex grou...
L-Cysteine Hydrochloride Monohydrate
About the Company : We specialize in the supply of API and API related intermediates and services. A significant part of our business comes from the process/production development tailored to our cust...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
U.S.FDA granted company,180 days of generic exclusivity as a result of being the first ANDA submitted for cysteine hydrochloride injection, a bioequivalent generic of Exela Pharma Sciences’ Elcys, against the reference product.
Lead Product(s): L-Cysteine Hydrochloride
Therapeutic Area: Nutrition and Weight Loss Brand Name: Cysteine Hydrochloride - Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2022
Lead Product(s) : L-Cysteine Hydrochloride
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
Details : U.S.FDA granted company,180 days of generic exclusivity as a result of being the first ANDA submitted for cysteine hydrochloride injection, a bioequivalent generic of Exela Pharma Sciences’ Elcys, against the reference product.
Brand Name : Cysteine Hydrochloride - Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - SOLUTION;INTRAVENOUS - 2500MG/50ML (...DOSAGE - SOLUTION;INTRAVENOUS - 2500MG/50ML (50MG/ML)
USFDA APPLICATION NUMBER - 210660
DOSAGE - SOLUTION;INTRAVENOUS - 500MG/10ML (5...DOSAGE - SOLUTION;INTRAVENOUS - 500MG/10ML (50MG/ML)
USFDA APPLICATION NUMBER - 210660
Digital Content
NEWS #PharmaBuzz
Market Place
APIs
Reply
18 Jul 2024
Reply
25 Jan 2024
Reply
30 Sep 2023
Reply
08 Mar 2023
Reply
17 Jan 2023
Reply
15 Sep 2022
Reply
12 Apr 2022
Reply
20 Nov 2021
Reply
18 Nov 2021
Reply
25 Oct 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EXCIPIENTS
Reply
12 Feb 2024
Reply
28 Sep 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2039-01-15
US Patent Number : 11648262
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212535
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 11642370
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212535
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 10933089
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212535
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-03-15
US Patent Number : 10493051
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212535
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-15
Patent Expiration Date : 2039-03-15
US Patent Number : 10543186
Drug Substance Claim :
Drug Product Claim :
Application Number : 212535
Patent Use Code : U-2722
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-03-15
Patent Expiration Date : 2039-01-15
US Patent Number : 10905713
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 212535
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 10905714
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210660
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 10478453
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210660
Patent Use Code : U-2752
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 10583155
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210660
Patent Use Code : U-2752
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
Patent Expiration Date : 2039-01-15
US Patent Number : 11648262
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210660
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-01-15
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Comment (1)
